Sucampo Pharmaceuticals (SCMP) : Traders are getting increasingly bearish on Sucampo Pharmaceuticals (SCMP), as can be seen in the addition of short positions from 1,669,622 on Jul 29, 2016, to 1,745,819 on August 15, 2016. The net change in shorts is 76,197 shares, an increase of 4.6%. 4 days remain before the expiry. The 7.1% of outstanding short positions on the stock compared to its float, shows that traders expect the stock to fall from the current levels. The daily volume of the stock is 403,705. The short interest information was released on Wednesday Aug 24th after the market close.
Sucampo Pharmaceuticals (NASDAQ:SCMP): The stock opened at $11.42 on Wednesday but the bulls could not build on the opening and the stock topped out at $11.84 for the day. The stock traded down to $11.02 during the day, due to lack of any buying support eventually closed down at $11.09 with a loss of -3.48% for the day. The stock had closed at $11.49 on the previous day. The total traded volume was 310,564 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CFO of Sucampo Pharmaceuticals, Inc., Smith Andrew P, had purchased 1,605 shares in a transaction dated on November 16, 2015. The transaction was executed at $17.03 per share with total amount equaling $27,333.
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities. Its operations are conducted through Sucampo AG (SAG), based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Bethesda, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom. The Companys geographic segments are Asia, the Americas and Europe.